



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Fabhalta (iptacopan) Page: 1 of 4

Effective Date: 2/9/2026 Last Review Date: 1/2026

Applies to: Illinois Florida Florida Kids
 New Jersey Maryland Michigan
 Pennsylvania Kids Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Fabhalta under the patient's prescription drug benefit.

Description:

FDA-approved Indications¹

Fabhalta is indicated for:

- Treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) – **Reference the New Jersey State guideline: PNH products approved protocol addendum 10-24**
- To reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.
 - This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether Fabhalta slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
- Treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Fabhalta

Policy/Guideline:

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

For initial requests:

- Primary immunoglobulin A nephropathy (IgAN):
 - Kidney biopsy confirming a diagnosis of primary immunoglobulin A nephropathy (IgAN).
 - Laboratory report and/or chart note(s) indicating the member has proteinuria greater than or equal to 0.5 g/day or baseline UPCR greater



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Fabhalta (iptacopan) Page: 2 of 4

Effective Date: 2/9/2026 Last Review Date: 1/2026

Applies to: Illinois Florida Florida Kids
 New Jersey Maryland Michigan
 Pennsylvania Kids Virginia

than or equal to 0.8 g/g obtained within 3 months prior to initiation of the requested drug.

- Complement 3 glomerulopathy (C3G):
 - Kidney biopsy confirming a diagnosis of complement 3 glomerulopathy (C3G).
 - Laboratory report and/or chart note(s) indicating the member has proteinuria greater than or equal to 1 g/day or baseline UPCR greater than or equal to 1.0 g/g obtained within 3 months prior to initiation of the requested drug.
 - Laboratory report and/or chart note(s) showing a reduction in serum C3.

For continuation requests:

- Primary immunoglobulin A nephropathy (IgAN): Laboratory report and/or chart note(s) indicating the member has decreased levels of proteinuria or UPCR from baseline.
- Complement 3 glomerulopathy (C3G): Laboratory report and/or chart note(s) indicating the member has decreased levels of proteinuria or UPCR from baseline.

Prescriber Specialties

This medication must be prescribed by or in consultation with one of the following:

- Primary immunoglobulin A nephropathy (IgAN) and complement 3 glomerulopathy (C3G): nephrologist.

Coverage Criteria

Primary Immunoglobulin A Nephropathy (IgAN)^{1,8}

Authorization of 12 months may be granted for treatment of primary immunoglobulin A nephropathy (IgAN) when all of the following criteria are met:

- Member has a diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy.
- Member has either of the following obtained within 3 months prior to initiation of the requested drug:
 - Proteinuria greater than or equal to 0.5 g/day.
 - UPCR greater than or equal to 0.8 g/g.
- Member has received a stable dose of maximally tolerated renin-angiotensin system (RAS) inhibitor therapy (e.g., angiotensin converting enzyme inhibitor



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Fabhalta (iptacopan) Page: 3 of 4

Effective Date: 2/9/2026 Last Review Date: 1/2026

Applies to: Illinois Florida Florida Kids
 New Jersey Maryland Michigan
 Pennsylvania Kids Virginia

[ACEI] or angiotensin II receptor blocker [ARB]) for at least 3 months prior to initiation of therapy, or member has an intolerance or contraindication to RAS inhibitors.

Complement 3 Glomerulopathy (C3G)^{1,7}

Authorization of 12 months may be granted for treatment of complement 3 glomerulopathy (C3G) when all of the following criteria are met:

- Member has a diagnosis of complement 3 glomerulopathy (C3G) confirmed by kidney biopsy.
- Member has either of the following obtained within 3 months prior to initiation of the requested drug:
 - Proteinuria greater than or equal to 1 g/day.
 - UPCR greater than or equal to 1.0 g/g.
- Member has reduced serum C3 (defined as less than 0.85 times the lower limit of normal per the reference ranges provided) at baseline.
- Member has received a stable dose of maximally tolerated renin-angiotensin system (RAS) inhibitor therapy (e.g., angiotensin converting enzyme inhibitor [ACEI] or angiotensin II receptor blocker [ARB]) for at least 3 months prior to initiation of therapy, or member has an intolerance or contraindication to RAS inhibitors.

Continuation of Therapy

Primary Immunoglobulin A Nephropathy (IgAN)

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when all of the following criteria are met:

- There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
- The member is experiencing benefit from therapy as evidenced by either of the following:
 - Decreased levels of proteinuria from baseline.
 - Decrease in UPCR from baseline.

Complement 3 Glomerulopathy (C3G)

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when all of the following criteria are met:



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Fabhalta (iptacopan) Page: 4 of 4

Effective Date: 2/9/2026 Last Review Date: 1/2026

Applies to: Illinois Florida Florida Kids
 New Jersey Maryland Michigan
 Pennsylvania Kids Virginia

- There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
- The member is experiencing benefit from therapy as evidenced by either of the following:
 - Decreased levels of proteinuria from baseline.
 - Decrease in UPCR from baseline.

Approval Duration and Quantity Restrictions:

Initial Approval:

- Primary immunoglobulin A nephropathy (IgAN): 12 Months
- Complement 3 glomerulopathy (C3G): 12 Months

Renewal Approval: 12 Months

Quantity Level Limit: 60 capsules per 30 days

References:

1. Fabhalta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2025.
2. Parker CJ. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. *Hematology*. 2011; 21-29.
3. Borowitz MJ, Craig F, DiGiuseppe JA, et al. Guidelines for the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria and Related Disorders by Flow Cytometry. *Cytometry B Clin Cytom*. 2010; 78: 211-230.
4. Preis M, Lowrey CH. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH). *Am J Hematol*. 2014;89(3):339-341.
5. Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. *Hematology Am Soc Hematol Educ Program*. 2016;2016(1):208-216.
6. Dezern AE, Borowitz MJ. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility. *Cytometry B Clin Cytom*. 2018 Jan;94(1):16-22.
7. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int*. 2021 Oct; 100 (4S): S1-S276. doi: 10.1016/j.kint.2021.05.021.
8. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). *Kidney Int*. 2025 Oct; 108 (4S): S1-S71.